ArticleEcancermedicalscience2025
Patterns of cancer in Needle Hospital, Hargeisa, Somaliland from July 2022 to June 2023.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epidemiological risk factors and inferred p53 pathway dysregulation in Esophageal squamous cell carcinoma in the Somali population.Discover oncology · 2026Review
- Article
- Prevalence and pattern of cancers among patients attending Al-Hayat Hospital in Boorama, Somaliland.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Globally, the incidence of and mortality from cancer is rapidly increasing and presents a barrier to increasing life expectancy. Based on regional and global trends, cancer incidence in Somaliland is expected to increase. Until recently, there was no dedicated cancer clinic in Somaliland. In July 2022, a medical oncology service was started in Needle Hospital, Hargeisa, Somaliland. This study reports on patterns of cancer with respect to patients' region, age, gender, comorbidities, site and subsites of cancer, histology and stages. Patients and method: A retrospective study was conducted to determine the patterns of cancer among patients evaluated in the Needle Hospital cancer clinic from July 2022 to June 2023. Data were extracted from the cancer patient registration file and charts. Descriptive statistics were applied using the Statistical Package for the Social Sciences version 23. Results: A total of 232 cancer patients were evaluated during the study period. The median age was 60.0 years. More than half (56.5%) of the patients were female, with a female-to-male ratio of 1.3:1. Most of the patients (66.8%) came from Morodijeh, followed by Togdher (15.1%) and Awdal (5.2%) regions. The most common anatomic subsites of the cancers were breast, esophageal and prostate cancers, accounting for 15.9%, 8.2% and 7.3%, respectively. Based on histology, adenocarcinoma and squamous cell carcinoma accounted for 42.2% and 25%, respectively. Most patients presented at an advanced stage; stage IV cancer accounted for 44.4% and stage III cancers accounted for 29.30% of the total patients. Conclusion: Based on this study, cancer is one of the emerging health problems in Somaliland. Most patients presented at an advanced stage. Breast, esophageal and prostate cancers were the most commonly diagnosed cancers. Esophageal cancer, being a common finding, is disparate, so a study investigating the aetiology and biology of esophageal cancer in Somaliland is recommended. We also recommend establishing the National Cancer Control Plan, a national cancer registry and developing research capacity. Finally, to improve cancer outcomes, capacity building in diagnostic and treatment facilities and regional and international collaboration should also be prioritised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.